Identification of a new selective ligand for targeting neuronal KV4.3/KChIP3 over cardiac KV4.3/KChIP2 channels

Read full text Summarise with VIRAT
Authors: Paula G. Socuéllamos, Carmen Viedma-Barba, Ángela de Benito-Bueno, M. Ángeles Bonache, Maria Ropero, Sara Diez, Pablo Elizalde, Irene Marín-Olivero, María Redondo-Moya, José R. Naranjo, Juan Antonio Gonzalez‐Vera, Ángel Orte
+4 more Ángel Pérez-Lara, Mercedes Martín‐Martinez, Carmen Valenzuela, Marta Gutiérrez‐Rodríguez
Cited by: 0
References: 47

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The present study aimed to discover novel KChIP ligands as pharmacological tools for modulating the K V 4.3/KChIP channels. A multidisciplinary approach, combining medicinal chemistry and electrophysiology studies, led to the successfully identification of a novel K V 4.3/KChIP modulator (IQM-22110). Its design was guided by the previous knowledge of the (phenylacetamido)benzoic acid moiety as suitable scaffold, along with virtual screening of a focused chemical library that suggested improved KChIP3 binding upon incorporation of an additional aromatic ring. IQM-22110 was selected for synthesis and identified as a potent KChIP3 ligand. Its electrophysiological effects on K V 4.3/KChIP3 currents indicate that IQM-22110 binds to a high affinity site in K V 4.3/KChIP3 channels that it is not present in K V 4.3/KChIP2 or K V 4.3. To the best of our knowledge, here we describe the first KChIP3 ligand that selectively modulates K V 4.3/KChIP3 versus K V 4.3/KChIP2 and K V 4.3 channels at nanomolar concentration. Since KChIP2 is predominantly expressed in cardiac tissue, this selectivity may enable the development of K V 4.3/KChIP3-targeted therapeutics with reduced risk of cardiac side effects. Computational and site-directed mutagenesis studies allowed the identification of IQM-22110′s binding site on KChIP3. Knowledge gained from structural and functional studies with this novel KChIP3 ligand could establish the basis for drug discovery programs fostering treatments for diseases in which K V 4.3/KChIPs channels are involved.

Fields of Study & Subjects

Ion channel regulation and function Cardiac electrophysiology and arrhythmias Nicotinic Acetylcholine Receptors Study

Publication details

Journal / source
Biochemical Pharmacology
Volume
249
Pages
117921–117921
Publication date
21 March 2026
Language
EN